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Long-lived reservoirs of persistent HIV are a major
barrier to a cure. CD4+ hematopoietic stem and pro-
genitor cells (HSPCs) have the capacity for lifelong
survival, self-renewal, and the generation of daughter
cells. Recent evidence shows that they are also sus-
ceptible to HIV infection in vitro and in vivo. Whether
HSPCsharbor infectious virus or contribute to plasma
virus (PV) is unknown. Here, we provide strong evi-
dence that clusters of identical proviruses from
HSPCs and their likely progeny often match residual
PV. A higher proportion of these sequences match
residual PV than proviral genomes from bonemarrow
and peripheral blood mononuclear cells that are
observed only once. Furthermore, an analysis of
near-full-length genomes isolated from HSPCs pro-
vides evidence that HSPCs harbor functional HIV pro-
viral genomes that often match residual PV. These
results support the conclusion that HIV-infected
HSPCs form a distinct and functionally significant
reservoir of persistent HIV in infected people.
INTRODUCTION
Combination anti-retroviral therapy (cART) efficiently blocks HIV
replication in vivo. However, the virus is able to persist within in-
fected individuals and rebound viremia frequently occurs if cART
is interrupted (Davey et al., 1999). Failure of cART is thought to
result from persistent long-lived cells that harbor integrated
HIV genomes that are unaffected by anti-retroviral therapy.
Restingmemory CD4+ T cells are a well-characterized HIV reser-
voir (Chun et al., 1997; Finzi et al., 1997, 1999). In addition,
emerging data support the possibility that non-CD4+ T cells
may also form persistent HIV reservoirs (Araı´nga et al., 2017;
Avalos et al., 2016; Honeycutt et al., 2017; Sundstrom et al.,
2007; Zhu et al., 2002). In particular, hematopoietic stem and
progenitor cells (HSPCs) are a long-lived cell type that has
been shown to be infected in vivo and is capable of propagating
integrated provirus to CD4+ and CD4 progeny (Carter et al.,
2010; Sebastian et al., 2017). Moreover, infected HSPCs can
produce virions upon latency reversal in vitro (Zaikos et al.,
2018). Therefore, it is possible that HSPCs could contribute to
persistent and rebound viremia directly or by serving as a source
of infected daughter cells that can be activated to produce virus.
Residual plasma virus (PV), defined here as a PV level of less
than 48 copies per mL, can be detected in treated people by
ultra-sensitive techniques even when virus is undetectable by
standard clinical tests. Sequence analysis of residual PV and
rebounding PV in HIV-infected people indicates that virions likely
come from the activation of latent provirus that had been
archived since before the initiation of therapy rather than from
low-level replication and spread of cART-resistant virus (Eisele
and Siliciano, 2012; Kearney et al., 2014).
The cellular source of residual virus remains poorly under-
stood. A number of studies have shown that proviral DNA from
CD4+ T cells and other peripheral blood mononuclear cells
(PBMCs) frequently does not match residual PV (Bailey et al.,
2006; Brennan et al., 2009; Buzon et al., 2014; Chun et al.,
2000; Sahu et al., 2009). One small study of two donors found
that virus induced ex vivo from a subset of activated T cells
matched residual PV, leading the authors to conclude that it is
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Figure 1. A Signature Deletion Marks a Clonal, HSPC-Associated-Proviral Genome that Releases Non-infectious Clonal Virus In Vivo and
Ex Vivo
(A) HIV genome map and identical viral sequences from indicated tissue source from donor 436000. The solid bars indicate fully sequenced, genetically intact
amplicons. The black and white hatched bars indicate the location of a signature deletion with nucleotide sequence shown in the figure insert. The solid red bar
indicates sequenced human chromosome 9:HIV integration site, with nucleotide sequence shown in figure insert. The thin line connecting gag and env amplicons
indicates sequences that originated from the same first-round reaction performed at limiting dilution. The number of times a sequence was observed is indicated
by a separate rectangle or by a number (x n).
(B) Maximum-likelihood phylogenetic trees of gag and env HIV sequences from the indicated tissue sources. Identical sequence groups are designated with a
red bar, and the number of symbols represents the number of times the sequence was observed. Identical sequence groups depicted in (A) are marked with the
circled asterisk. Scale indicates nucleotide substitutions per site.
(C) Summary graph of HIV mRNA abundance in supernatant from a viral outgrowth assay using CD4+ cells isolated from donor 436000 BMMCs. Cells were
stimulated with PMA and ionomycin or matched DMSO solvent control. The dashed line indicates limit of detection for the assay. The viral outgrowth assay was
performed once with all samples analyzed in duplicate in the qPCR assay.
(legend continued on next page)
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possible that residual PV may originate from a minor population
of circulating CD4+ T cells (Anderson et al., 2011). Whether
HSPCs contribute to residual PV is unknown.
Genetic characterization of provirus from CD4+ T cells has
demonstrated that many are defective and that defective provi-
ruses rapidly accumulate (Bruner et al., 2016; Hiener et al., 2017;
Imamichi et al., 2016). Analyses of near-full-length proviral ge-
nomes indicate that 2%–12%of CD4+ T cell-derived HIV proviral
genomes have full open reading frames (Bruner et al., 2016; Hi-
ener et al., 2017; Ho et al., 2013). Whether provirus from HPSCs
is defective has not previously been examined.
A determination that proviral genomes from HSPCs contain
open reading frames that match residual PV would provide evi-
dence that HSPC-derived genomes are indeed functional.
Here, we examine provirus and residual PV from HSPCs and
other cell types from a cohort of 24 donors, providing evidence
in support of this conclusion.
RESULTS
Single-Genome Amplification of Proviral DNA from
HSPCs and Other Cellular Subsets
We recruited 53 HIV-infected donors on cART with viral loads
<48 copies per mL. We obtained samples of blood and bone
marrow from each donor. Ten donors were excluded for insuffi-
cient sample size or suboptimal HSPC sort purity. Table S1 sum-
marizes the characteristics of the included donors. Ten donors
contributed samples more than once over periods spanning
4 months to nearly 5 years (Table S1). For each included donor,
we isolated two different types of HSPCs in sequential sorts
(CD133+ [sort 1] or CD34+CD133– [sort 2]). Each sort was
analyzed individually for purity. We excluded any individual
HSPC sorts that were <80% HSPCs or >1% CD3+ cells (Fig-
ure S1A). Inmost cases, included samples were well within these
criteria, with mean purity 90% or higher and mean CD3+ T cell
contamination rates less than 0.4% (Table S2).
To determine whether HSPCs serve as a source of PV, we
amplified individual HIV proviral genome sequences from highly
purified HSPCs, HSPC-depleted bone marrow mononuclear
cells (BMMCs), and PBMCs. For this analysis, we used a highly
sensitive multiplex PCR protocol that was performed at limiting
dilution to amplify individual gag or env sequences in separate
second-round reactions (Sebastian et al., 2017). This protocol
was applied to DNA from both HSPC populations (CD133+
[sort 1] and CD34+CD133– [sort 2]), providing four assays for
each donor’s progenitor cells (gag and env PCRs using samples
from sort 1 and sort 2). Based on the sort purity and the
frequency of HIV provirus in CD3+ samples, we performed a
statistical analysis to determine the likelihood that provirus was
amplified from contaminating CD3+ cells rather than an HSPC
(McNamara et al., 2013; Sebastian et al., 2017). Only samples
that yielded HIV proviral DNA that was unlikely to be due to
T cell contamination were included in our final analyses (Fig-
ure S1B). Figure S1C summarizes the proportion of donors
who had positive results in each of the four assays.
Additionally, all viral sequences were compared phylogeneti-
cally to every previously acquired sequence and lab strain to
rule out cross-contamination. All included donor sequences
clustered appropriately except for outliers that contained
frameshifts.
We determined that 25 of the 43 included donors had detect-
able provirus in HSPC DNA. Sort purity and CD3+ T cell contam-
ination levels were very similar between the donors who had
detectable HIV provirus in HSPC DNA and those that did not
(Table S2). However, we did note a trend toward a lower yield
of HSPCs available to screen for the negative donors (Table S2).
Isolation and Characterization of Residual PV
For each donor, we also harvested plasma from which we iso-
lated residual PV. Purified viral RNA was converted to cDNA,
and HIV sequences were amplified using the multiplex PCR
described above. We successfully detected residual PV in sam-
ples from 24 out of 25 donors who had provirus isolated from
HSPC DNA, including one donor who initiated cART during the
acute phase (donor 503501; Table S1).
To identify potential cellular sources of residual PV, we
compared all PV sequences to all proviral DNA sequences. As
expected, some of the PV matched provirus from PBMCs and
BMMCs, a large percentage of which are T cells. However,
phylogenetic analysis revealed that proviral sequences isolated
from highly purified HSPCs exactly matched amplified residual
PV in 8 of 24 donors. We noted significantly higher mean CD4
counts at the time of sampling and a greater number of PV am-
plicons recovered per donor in the 8 donorswithmatching HSPC
and PV sequences (p = 0.0005 and p = 0.04, respectively; Table
S3). The phylogenetic analysis for these sequences for each of
the 8 donors is shown in Figures 1, 2, 3, and 4, and Figures S2,
S3, S4, and S5. An analysis of genetic diversity based on average
pairwise genetic distance (APD) indicated that donors with
matching HSPC proviral DNA and PV had a similar degree of ge-
netic diversity as those that did not (Table S4). Themean APD for
provirus was >1% and the mean APD for PV was >0.5% for both
groups. As expected, env sequences were significantly more
diverse than gag sequences (p < 0.05). Based on the APD, the
length of the amplicons and the number of observed versus ex-
pected identical sequences, the probability the observed
(D) Summary graph of packaging efficiency of wild-type HIV reporter construct (NL4-3 DGPE-GFP wild-type [WT]) or the reporter construct containing the
deletion shown in (A). Reporter virus constructs were transfected into 293T cells with helper plasmids as indicated. Packaging efficiency was calculated by
dividing the abundance of HIV mRNA in the supernatant by the normalized cell-associated HIV mRNA from each sample. Results are normalized to that of WT
reporter co-transfected with helper plasmids. Results are from two biological replicate experiments with the deleted construct tested in duplicate in one. Samples
were analyzed in triplicate in the PCR assay.
(E) Summary graph of reporter virus Env expression in transfected 293T cells with replicates as in (D) (left panel) and infected CEM-SS T cells as assessed by the
frequency of GFP+ cells detected by flow cytometry (three biological replicates; right panel). For infections, CEM-SS cells were treated with transfected cell
supernatant containing equal numbers of HIV copies by qPCR. Error bars indicate SD.
See also Tables S1–S5 and Figures S1, S6, and S7.
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Figure 2. HSPC-Associated Sequences Match PV and Can Be Recovered from Two Donations Separated by 10 Months
(A) HIV genome map and identical viral sequences from the indicated tissue source from donor 435412406. Boxes indicate fully sequenced, genetically intact
amplicons. The number of times a sequence was observed is indicated by a separate rectangle or by a number (x n).
(legend continued on next page)
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identities across these amplicons occurred by chance sampling
from the population was very low (p < 106; Table S5) (Bui et al.,
2017).
Sequence identity across entire amplicons is suggestive that
PV was derived from the matching proviral genome. The likeli-
hood that sequences identical over the C2-V3 env region repre-
sent identity over the entire HIV genome can be estimated at
83% using a previously published clonal prediction score (Las-
key et al., 2016). In some cases, the multiplex single-genome
amplification (SGA) PCR generated both an 828-bp fragment
from the 50 long terminal repeat (LTR) into the gag open reading
frame as well as 429 bp of env C2-V3 allowing us to link two
amplicons to the same genome (Figures 1, 3, 4, and S4). Linkage
between the two loci was also achieved by the isolation of
9,000-bp near-full-length genomes (Figure 3). When matching
was achieved at both locations, the likelihood that the genomes
were clonal was even higher. Our findings of sequence identity
acrossmultiple locations within the HIV proviral genome strongly
support the conclusion that PV sequences were derived from
matching proviral genomes and are consistent with our analysis
showing that these identities were unlikely to have occurred by
chance (Table S5).
Evidence that Residual PV Is Derived from Clusters of
HSPC-Associated Identical Proviral Genomes
It was relatively common in our cohort for PV to exactly match
proviral sequences fromHSPCs; across the 24 donors analyzed,
when unique sequences were compared, a higher proportion of
proviral genomes from HSPCs matched PV (9% of gag and 13%
of env amplicons) than genomes derived from PBMC or BMMC
(3% gag and 4% env; p < 0.05) (Figure 5A). All of the HSPC-
associated proviral genome sequences that matched PV also
matched identical clusters of proviral genomes from PBMCs or
BMMCs (Figure 5B). When these identical sequences include
at least four proviral amplicons from non-HSPC cells, we refer
to them as clusters of HSPC-associated identical proviruses
(CHIPs). Remarkably, approximately 50% of CHIPs could be
matched to PV (Figure 5B).
The impact of CHIPs is apparent when comparing Figure 5A
(unique sequences only) to Figure 5C (all sequences). Because
CHIPs commonly match PV, when all identical copies of provirus
from BMMCs and PBMCs were included in the analysis, signifi-
cant differences observed in Figure 5A were lost. These results
suggest that clonally amplified sequences make important con-
tributions to residual PV.
To further examine the relationship between clonally amplified
sequences and PV, we examined a sub-group of 16 donors that
had (1) clonal proviral sequences thatmatched anHSPC-derived
provirus and (2) clonal proviral sequences for which we did not
identify an HSPC match. We found that both types of ‘‘clonal’’
proviral sequencesmore frequently matched PV than sequences
that were only isolated once (2% total versus 0.3% for non-
clonal sequences; Figure 5D). Proviral sequences matching
HSPC-derived provirus were prominent among PV-matching
clonal sequences, contributing about one-half of the total clonal
proviruses matching PV, despite contributing a smaller fraction
of total proviruses (3% versus 9%; Figure 5D).
To avoid potential clustering effects of individual participants,
we also analyzed the data by determining the proportion of
residual PV matching provirus within each donor rather than
pooling sequences across all donors. This analysis, shown in
Figure 6A, similarly demonstrated that clonal sequences more
frequently contributed to PV. Notably, the differences were
most significant for sequences that were likely to be both clonal
and derived from HSPCs (p < 0.001). These results identify a
unique relationship between clonally amplified proviral ge-
nomes and residual PV. They also suggest that HSPCs are
important for generating some of these clusters of amplified se-
quences in some donors.
Evidence that Virions Matching CHIPs Are Often
Predominant in the Plasma
Five donors (434423, 436000, 449000, 454304, and 458311) had
large groups of identical residual PV sequences that qualify as
predominant plasma clones (PPCs). A PPC is a single sequence
representing more than 50% of a large sample of independent
plasma sequences from a given patient (Bailey et al., 2006).
For two donors (434423 and 436000), these sequences matched
CHIPs. In the remaining three donors, no cellular source of PPCs
was identified (Figures 6B and 6C). Thus, CHIPs account for
PPCs in at least a subset of donors.
A Signature Deletion Found in Both a CHIP and a PPC
Supports HSPCs as an Original Source of Viremia
While exact matches over gag and env C2-V3 regions provide
strong evidence that genomes are clonal, it remains theoreti-
cally possible that sequence differences are present elsewhere
in the genome. This is an important consideration as infection
by genetically similar viruses could mimic clonality that arises
by cellular proliferation and expansion of genetically identical
viruses. We were able to exclude coincidental infection as an
explanation in one donor (Figure 1). In this donor, proviral
genomes frommultiple cellular sources, including HSPCs, con-
tained a signature deletion. This deletion, which likely occurred
at the time of reverse transcription, eliminated the tRNA(Lys3)
primer binding site (pbs), the major splice donor, the dimeriza-
tion initiation site, and the first two packaging stem loops. Due
to the loss of the pbs and the major splice donor, virus gener-
ated from this proviral genome cannot initiate reverse transcrip-
tion or produce Env and is thus noninfectious. However, the
defects harbored by the provirus are not expected to block
transcription or eliminate packaging of the RNA genome as
SL3 is sufficient for RNA genome packaging (Abbink and
Berkhout, 2008). Consistent with this, we identified 23 clonal
(B) Maximum-likelihood phylogenetic trees of gag and env HIV sequences from indicated tissue sources. Identical sequence groups are designated with a
red bar, and the number of symbols represents the number of times the sequence was observed. Identical sequence groups depicted in (A) are marked with the
circled numbers. Scale indicates nucleotide substitutions per site. Sequences from the first, second, and third donations are represented by symbols that are
empty, struck-through, and filled, respectively.
See also Tables S1–S5 and Figure S1.
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Figure 3. A Near-Full-Length Proviral Genome with Intact Open Reading Frames from HSPCs Matches PV Detected in Two Donations
Separated by 3.8 Years
(A) HIV genome map and identical viral sequences from indicated tissue sources from donor 454304. The solid bars indicate fully sequenced, genetically intact
amplicons. The thin line connecting gag and env amplicons indicates sequences that originated from the same first-round reaction performed at limiting dilution.
The number of times a sequence was observed is indicated by a separate rectangle or by a number (x n).
(legend continued on next page)
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copies of residual PV harboring the deletion (Figure 1). Addi-
tionally, a viral outgrowth assay performed using CD4+ T cells
isolated from BMMCs activated with phorbol 12-myristate
13-acetate (PMA) and ionomycin ex vivo, yielded virions con-
taining genomic RNA with the identical signature deletion in
the LTR/gag amplicon plus the identical C2/V3 env region (Fig-
ures 1A–1C). The deleted RNA was a major component of total
released viral RNA sequences (80%). The isolated genomes
were derived from RNA as we obtained no sequences when
reverse transcriptase was omitted (Figure 1C). This evidence
supports the conclusion that the deleted virus is packaged
and released from cells.
To verify this conclusion, we sub-cloned the deletion into an
HIV reporter construct that requires gag in trans for virion pro-
duction (Figure S6). Wild-type reporter virus was released into
the supernatant 335-fold more efficiently when Gag was pro-
vided in trans (Figure S6B). The deletion found in the donor
436000-derived provirus, which removes the portion of the
packaging signals contained in stem loops 1 and 2, resulted in
a 4-fold reduction in packaging efficiency compared to wild-
type, but still packaged over 80-fold more efficiently than wild-
type reporter virus in the absence of Gag, demonstrating that
genomic RNA containing this deletion was specifically released
in Gag-containing particles (Figure 1D). A positive result in this
assay depended on the addition of HIV template and reverse
transcriptase, confirming that the positive signal did not originate
from contamination or residual HIV DNA (Figure S6). Contami-
nating DNA was eliminated by the addition of DNase prior to
reverse transcription, which we show efficiently eliminated signal
from an HIV DNA control (Figure S6). Thus, the deleted proviral
genome from donor 436000 retained the capacity to produce
virions containing HIV genomic RNA.
Although the genomic RNA was packaged, it was unlikely to
be infectious due to the loss of the primer binding site as well
as the major splice donor. To confirm this, we measured cellular
HIV mRNA and expression of the Env-GFP fusion protein ex-
pressed by this reporter construct (Figure S6). We detected
HIV mRNA in cells expressing both wild-type and deleted re-
porter constructs (Figure S6), but only the wild-type version pro-
duced Env-GFP in transfected cells (Figure 1E). Supernatants
containing virions with the deleted viral genome did not infect a
CD4+ T cell line, whereas control supernatants containing equal
copy numbers of wild-type viral genomes were infectious in our
assay (Figure 1E). These results confirm that the deleted provirus
is non-infectious and that spread to multiple cells in vivo must
have occurred by cellular proliferation of an infected progenitor
cell or its progeny. To provide further proof of this conclusion,
we used an established protocol to isolate HIV integration
sites. We identified an integration site on chromosome 9
associated with the signature deletion. We then used chromo-
some 9-specific primers to confirm the location of the integration
site. Using SGA PCR, we isolated multiple clonally amplified
copies of the identical integration site associated with the
same signature deletion (Figures 1A and S7).
HSPCs Harbor Intact, Near-Full-Length HIV Genomes
To determine whether provirus from HSPCs was infectious, we
amplified near-full-length proviral genomes fromHSPCs isolated
from 28 donors. For this assay, we used first-round PCR primers
within the viral LTRs and screened these products for near-full-
length genomes using primers that amplified a 400-bp env
fragment in a second-round reaction. Positive first-round reac-
tions were amplified with nested internal LTR primers and
sequenced to determine whether or not each individual near-
full-length genome was functional. In all, we identified 21 near-
full-length genomes from 10 donors. Twenty amplicons from
9 donors were unlikely to have been due to T cell contamination
of our HSPC samples based on the analysis described in
Figure S1. We obtained PCR products sufficient to assess the
integrity of 18 HIV genomes and fully sequenced 9. Five of
18 genomes, or 28%, had open reading frames for all 9 HIV
genes (Figures 7A and 7B). Four near-full-length genomes con-
tained intact cis elements in the 30 LTR. One proviral genome
from donor 409000 was missing the tRNA(Lys3) pbs (Figures
7A and S2). The four proviral genomes with intact LTR se-
quences were further tested to assess LTR function. As shown
in Figure 7C, the reconstructed LTRs were functional based on
expression of a downstream marker gene and their expression
was, as expected, Tat responsive. To provide further evidence
that these proviral genomes were infectious, we reconstructed
the provirus isolated from HSPCs from donor 454304 and
demonstrated that it produced fully infectious virus in vitro (Fig-
ures 7D–7F).
Strikingly, of the 5 genomes with intact open reading
frames, 3 (60%) exactly matched residual PV sequences as
well as proviral genomes from PBMC and BMMC. This in-
cludes the infectious proviral genome from donor 454304 in
which both env and gag were identical to residual PV (Figures
3 and 7A). Donor 409000 produced 2 intact genomes, one of
which had identity to a PV env amplicon (Figures 7A and
S2). From donor 421, we found an HSPC-derived near-full-
length sequence that was identical to a PV env amplicon (Fig-
ures 7A and S3). These intact genomes account for 10%–14%
of unique residual PVs found in these donors. Moreover,
sequence identity to proviral genomes from PBMCs and
BMMCs provides evidence that these genomes can clonally
expand in vivo (Figure 7).
Virions Matching HSPC Proviral Genomes Are
Persistently Present in Plasma
Three of the 8 donors with identical PV and HSPC-derived viral
sequences provided tissue samples on more than one occasion
(435412406, 454304, and 434423). For each of these donors, we
(B)Maximum-likelihood phylogenetic trees of gag and envHIV sequences from the indicated tissue sources. Identical sequence groups are designated with a red
bar, and the number of symbols represents the number of times the sequence was observed. Identical sequence groups depicted in (A) are marked with the
circled asterisk. Scale indicates nucleotide substitutions per site. Sequences from the first and second donations are represented by symbols that are empty and
filled, respectively.
See also Tables S1–S5 and Figure S1.
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were able to demonstrate persistent matching between PV and
HSPC proviral genomes over time.
Donor 435412406 contributed blood and bone marrow three
times over 10months, andwewere able to detect unique proviral
genomes in HSPCs from all three donations. Of note, a CHIP
from the first donation matched sequences found in PV from
the third donation. Conversely, a CHIP from the third donation
was identical to PV from the first donation (Figure 2).
Donor 454304 had a suppressed viral load for 3.3 years at
the time of the first donation and provided tissue again almost
4 years later. Described as donor 304000 in an earlier study,
HSPCs from this donor’s first donation had detectable HIV
Figure 4. Multiple (gag and env) HSPC-Associated HIV Sequences Matching a Predominant Plasma Clone Are Detectable in Two Donations
Separated by 4 Months
(A) HIV genomemap and identical viral sequences from the indicated tissue source from donor 434423. The solid bars indicate fully sequenced, genetically intact
amplicons. The thin lines connecting gag and env amplicons indicate sequences that originated from the same first-round reaction performed at limiting dilution.
The number of times a sequence was observed is indicated by a separate rectangle or by a number (x n).
(B) Maximum-likelihood phylogenetic trees of gag and env HIV sequences from indicated tissue sources. Identical sequence groups are designated with a
red bar, and the number of symbols represents the number of times the sequence was observed. Identical sequence groups depicted in (A) are marked with the
circled asterisk. Scale indicates nucleotide substitutions per site. Sequences from the first and second donations are represented by symbols that are empty and
filled, respectively.
See also Tables S1–S5 and Figure S1.
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provirus by a LTR/gag qPCR assay (McNamara et al., 2013).
Using our multiplex SGA, we isolated residual PV from both
donations that generated env amplicons identical to an infec-
tious genome (Figures 7D–7F). Two gag amplicons derived
from residual PV from the second donation also exactly matched
the functional proviral genome (Figure 3).
Donor 434423 provided blood and bone marrow twice over
4 months. A CHIP from the second donation, 434, matched
large clonal clusters of residual PV for both gag and env ampli-
cons (Figure 4). Among the reactions that were performed at
limiting dilution, 2 PV PCRs produced both gag and env that
were identical to HSPC-derived gag and env amplicons (Fig-
ure 4A). As discussed above, the presence of matching gag
and env sequences from multiplex SGA reactions for both
HSPC and PV strongly supports identity across the entire
genome. These examples provide strong support for the
conclusion that HSPC-associated genomes contribute to
persistent residual viremia.
DISCUSSION
Here, we confirm a prior study providing evidence that HSPCs
propagate HIV proviruses by cellular proliferation (Sebastian
et al., 2017) and provide evidence that clonally expanded
Figure 5. Residual PV Is Often Derived from Clusters of HSPC-Associated Identical Proviral Genomes
(A) Proportions of unique gag and env proviral sequences from HSPCs, PBMCs, and BMMCs with identity to plasma virus (PV). Comparison of proportions of
sequence populations was performed using online calculators for two-tailed Z-test comparison of 1- or 2-sample proportions (https://www.socscistatistics.com/
tests/ztest). The total number of sequences in each category is provided in Table S6.
(B) Proportions of HSPC-derived gag and env sequences with sequence identity to PV or other proviruses. CHIPs represent groups of identical proviral
sequences from at least 1 HSPC-derived amplicon and 4 ormore non-HSPC cell sources. The number of sequences analyzed is indicated in the center of the plot.
(C) Proportions of HSPC, PBMC, and BMMC proviral sequences that are identical to PV when all sequences are analyzed, including multiples copies of identical
genomes. Analysis included sequences only from donors from whom we detected HIV nucleic acid in HSPCs and peripheral blood plasma (N = 24). (The total
number of sequences in each category is provided in Table S6.)
(D) Proportions of PBMC and BMMC-derived gag and env sequences matching PV and/or (1) any other PBMC or BMMC-associated HIV sequence that was not
also identical to an HSPC-associated provirus or (2) HSPC-associated proviruses. Data were derived from donors described in (A) who had both types of proviral
identities (HSPC and non-HSPC; N = 16 donors). Only unique sequences are shown. The number of sequences analyzed is indicated in the center of the plot.
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proviruses fromHSPCprogeny contribute to residual PV. Proviral
genome sequences from HSPCs were often identical to se-
quences isolated from PBMCs and BMMCs. In two donors, pre-
dominant plasma viral clones exactlymatchedHSPC-associated
sequences. Based on these studies, we propose that HSPCs and
their daughter cells containing clonal genomes are capable of
producing clonal virus that can predominate in the plasma.
Determining the exact identity of the infected daughter cells will
require additional studies. In a prior investigation, we found
that HSPCs could pass genomes to both CD4-positive and
CD4-negative progeny in some donors (Sebastian et al., 2017).
These relatively rare occurrences are consistent with our model
that HSPCs can spread HIV genomes by cell division and
differentiation.
Although viremia is relatively low during cART, it likely re-
quires substantial HIV production from infected cells. Thus,
it is unlikely that HSPCs alone, which represent 1% of
BMMCS, are directly responsible for this virus production.
Rather, we propose that a subset of PV is derived from clonal
proviral sequences found in both HSPCs and PBMC/BMMC
populations (clusters of HSPC-associated identical proviruses
[CHIPs]). In this model, HSPCs themselves remain latently in-
fected, preserving their longevity and ensuring viral persis-
tence. HPSCs contribute to residual PV indirectly via the gen-
eration of progeny containing clonal proviral genomes that
become activated to produce PV. Consistent with this, most
HSPCs are maintained in a quiescent state in vivo, which we
have shown is associated with viral latency in vitro (Painter
et al., 2017).
Although HSPCs represent a small population of cells, in a
subset of donors, HSPC-associated proviral genomes were
a quantitatively more important source of residual PV than
proviral genomes that were not associated with HSPCs.
Future studies are needed to understand the mechanism
behind this observation. It could reflect lower cytopathicity
of the virus in HSPCs compared to T cells. Unlike T cell
models of latency, latency in HSPCs is immediately estab-
lished upon integration (Carter et al., 2010, 2011; McNamara
et al., 2012; Painter et al., 2017; Sebastian et al., 2017; Zaikos
et al., 2018). This mechanism avoids cytotoxicity due to tran-
sient viral protein expression. In contrast, most T cell models
require a period of active viral expression followed by the
establishment of latency with return of the T cell to a quies-
cent state (Bosque and Planelles, 2009; Kim et al., 2014).
Another possibility is that most virus-producing T cells are
non-circulating, hence untested here. However, if that were
the case, we would expect to have detected a greater variety
of viruses in the plasma. For example, the CHIP containing a
deleted primer binding site was one of 8 gag PV sequences
isolated and represented 51% of the gag amplicons we ob-
tained (23 of 45 gag amplicons). For env amplicons, this clone
was one of 4 env PV sequences and represented 67% of env
amplicons (31 of 45 env amplicons). Bailey et al. (2006)
Figure 6. Proviral Genomes that Are Likely Clonal More Frequently
Match Residual PV, and Predominant Plasma Clones that Can Be
Attributed to a Cellular Source Often Match CHIPs
(A) Graphical analysis showing the relationship between PBMC and BMMC
proviral genomes that are identical to other sequences (non-HSPC or HSPC
proviral genomes) and PV. Data were derived from donors described in Fig-
ure 5Dwho had both types of proviral identities (HSPC and non-HSPC; N = 16).
Individual donors with non-zero values are indicated by colored symbols. Only
unique gag and env sequenceswere included. p valueswere determined using
two-tailed Wilcoxon matched pairs signed-rank test.
(B and C) Bar graphs showing number of (B) gag and (C) env PV amplicons that
matched amplicons from the indicated groups of cellular proviruses from the
5 donors fromwhomwe identified predominant plasma clones (PPCs). Groups
of identical PV sequences are indicated by horizontal bars within each stacked
bar graph. Groups of PPCs are indicated with an asterisk. Number of proviral
sequences analyzed is shown below x axis donor labels.
See also Tables S1–S5 and Figures S2–S5.
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similarly observed dominant viral clones for most patients they
examined on long-term cART. More recently, Wang et al.
(2018) performed longitudinal sampling of residual PV env am-
plicons. In four of eight individuals, they observed dominant
PV populations. The evidence showing only a few latently in-
fected clones (or progeny thereof) contributing to the bulk of
residual viremia in some donors supports the conclusion
that amplified clonal populations are an important source of
residual PV.
Clonally expanded T cells have been described, and it is
important to consider these cells as a potential source of clonal
residual PV whether or not they are progeny of an infected HSPC
(Bruner et al., 2016; Hiener et al., 2017; Lee et al., 2017; Maldar-
elli et al., 2014; Simonetti et al., 2016; Sun et al., 2015; Wagner
et al., 2014). Interestingly, a recent study suggests that these
clonal populations can wax and wane over time (Wang et al.,
2018). In several publications, expansion of clonal T cell popula-
tions was explained by insertion of the provirus into genes that
regulate cell growth and/or by antigenic stimulation of the
T cell receptor (Cohn et al., 2015; Maldarelli et al., 2014; Simo-
netti et al., 2016). We report a clonally amplified provirus that
likely originated from an HSPC. This proviral genome was inte-
grated into a region of chromosome 9 that is devoid of known
genes (Figures 1 and S7). Amplification of this provirus by cellular
proliferation is unlikely to be due to insertion into genes that regu-
late growth. Thus, we provide an example of clonal expansion of
Figure 7. HSPCs Contain Proviral HIV Ge-
nomeswith Complete Open Reading Frames,
Active LTRs, and Infectious Virus that Are
Represented in Residual PV with Relatively
High Frequency
(A) HIV genome map and near-full-length proviral
sequences from HSPCs and genetically identical
sub-genomic amplicons from other tissue sources.
All amplicons represented are from PCRs that were
performed at limiting dilution. The tissue or cell
source of a sequence is indicated by a separate
rectangle. Donor IDs for groups of amplicons are
indicated on the left. For donor 454304, amplicons
from the first and second donations are represented
by empty and filled bars, respectively.
(B) Pie graphs showing the proportion of intact near-
full-length HIV genomes from HSPCs (left) and the
proportion of these intact sequences that are
genetically identical to sub-genomic amplicons
from residual PV (right). The number of sequences
analyzed is indicated in the center of the plot.
(C) Summary graph depicting the activity of re-
constructed LTR sequences from near-full-length
genomes isolated from HSPCs as assessed by the
frequency of transfected 293T cells expressing a
marker gene (GFP) that was under the control of the
LTR. Responsiveness to Tat was assessed by
co-transfection of a Tat-expressing plasmid where
indicated. Three biological replicates are shown.
The frequency of GFP-expressing cells are pre-
sented for each replicate.
(D) Summary graph of p24 production by the indi-
cated molecular clone following transfection of
293T cells (left panel) or infection of MOLT4-R5
T cells (right panel). Three technical replicates of
p24 ELISAs for three technical replicate infections of
MOLT4-R5 are shown.
(E) Representative flow-cytometric analysis of
MOLT4-R5 cells infected with the indicated virus
produced in MOLT4-R5 cells from (D) and stained
for intracellular Gag 4 days post-infection.
(F) Summary graph showing relative number of in-
fected cells over time from the infection described in
(E). After staining, all wells were resuspended in a
fixed volume of fluorescence-activated cell-sorting
(FACS) buffer and collected on a BD FACSCAN DxP
for 40 s so relative numbers of cells could be
compared across wells. MOLT4-R5 infection was
performed in three technical replicates, and the
mean number of cells expressing intracellular Gag
for each replicate is displayed. Error bars are SD.
Cell Reports 25, 3759–3773, December 26, 2018 3769
an HIV-infected cell due to the innate proliferative capacity of the
infected cell(s).
To the best of our knowledge, the frequency with which clon-
ally expanded populations contribute to residual PV has not
been reported. In our study, a significantly higher frequency of
clonally expanded proviral genomes matched residual PV, and
this difference was most significant when the clonally expanded
proviral populations were likely derived from an HSPC. The evi-
dence from our cohort supports the conclusion that HSPC-
derived clonal populations are an important source of PV, at least
in some donors, but are unlikely to be the only source of PV.
We also provide evidence that HSPC-associated HIV ge-
nomes are functional. A relatively high percentage of proviral
genomes isolated from HSPCs contained complete open
reading frames for all 9 viral genes (28%). This compares to
2%–12% for CD4+ T cells (Bruner et al., 2016; Hiener et al.,
2017; Ho et al., 2013). All of the intact proviral genomes tested
had LTRs that were functional in vitro. Moreover, we confirmed
that one of these genomes was infectious by showing that the
fully reconstructed provirus encoded infectious virus when
tested in vitro. Remarkably, HSPC-derived near-full-length
genomes often matched PV (60%). This ‘‘in vivo outgrowth
assay’’ provides strong evidence that HSPCs can harbor infec-
tious HIV.
The relative paucity of HSPC-derived HIV sequences
compared to those of PBMCs and BMMCs may have led to
under-sampling of the genomes harbored within HSPCs. Given
this, it is even more remarkable that HSPC-associated ge-
nomes matched PV more frequently than unique genomes
from PBMCs or BMMCS. Based on the frequency with which
gag and env PBMC-derived amplicons matched PV sequences
(3% and 4%, respectively), we would have expected that only 2
(gag) and 3 (env) HSPC-derived proviral amplicons matched PV
sequences. Instead, we found 5 (gag) and 8 (env) HSPC-derived
amplicons matched PV. Based on the observed 3 (gag) and
5 (env) additional matching HSPC-derived amplicons and the
expected proportion of matching sequences (3% and 4%),
the probability that under-sampling overestimated that fre-
quency of HSPC genomes matching PV is extremely low
(<104).
Determining whether genomes with identical sequences
across an amplified segment are truly clonal can be challenging.
It is theoretically possible that identical sub-genomic proviral se-
quences harbored by HSPCs and other cell types were derived
from genetically similar viruses rather than truly clonal ones.
However, this is an unlikely explanation for our results for a
number of reasons: (1) identity was observed across the entire
variable C2-V3 env amplicon, which is associated with a clonal
prediction score of 83% (Laskey et al., 2016); (2) we were often
able to exactly match both gag and env amplicons from the
same first-round SGA PCR, increasing our confidence in clonal-
ity; (3) one CHIP that matched a PPC contained a signature dele-
tion that removed the primer binding site (an 18-bp sequence
complementary to tRNA[Lys3] that is used to prime reverse
transcription), the major splice donor, and two stem loops. This
deletion caused the virus to be non-infectious, allowing the
conclusion that this viral genome was amplified by cellular
proliferation.
Multiple defects are present in the non-infectious genome
shown in Figure 1 (loss of the primer binding site, themajor splice
donor, and two stem loops). However, our evidence indicates
deletion of the primer binding site, which is needed for reverse
transcription, is the dominant mechanism for loss of infectivity.
Deletion of two stem loops reduced but did not prevent viral
genome packaging and virion release. Loss of the major splice
donor did not prevent in vivo expression or detection of viral
RNA in ex vivo outgrowth assays. The absence of the splice
donor element is expected to affect expression of factors (Tat
and Rev) that are needed for optimal expression of Gag and
the packaged genome. Residual expression could occur from
low-level Tat and Rev-independent transcription and nuclear
export. It is also possible that alternative splice donor sites pre-
sent in the proviral genome or in nearby genomic sequences
rescue Tat and Rev expression. Importantly, the virus remained
defective for infection even when Tat and Rev were provided
in trans. Thus, the primer binding site defect is sufficient to
render the virus non-infectious. The presence of this defective
proviral genome in multiple cells provides strong evidence for
spread of HIV genomes via cellular proliferation from an infected
progenitor. The isolation of multiple copies of identical integra-
tion sites containing this signature deletion confirms our
conclusion.
Loss of the tRNA binding site sequence by a genome that is
producing large amounts of virus raises the possibility that
this genetic element could regulate viral gene expression. Inter-
estingly, a number of studies have shown that transcriptional re-
pressors utilize tRNA binding sites in other retroviruses to
restrict viral transcription. Specifically, this element is required
for transcriptional silencing of murine leukemia viruses (MLVs)
that have integrated into genomes of embryonic stem cells.
The repression is largely mediated by trans-acting factors that
recognize the primer binding site (Wolf and Goff, 2007, 2008,
2009; Wolf et al., 2008a, 2008b). Whether a related trans-acting
factor might similarly regulate HIV gene expression via the HIV
tRNA binding site in cells with stem cell-like characteristics is
not yet known. Here, we report that PMA and ionomycin treat-
ment is required for release of the deleted virus from donor
CD4+ T cells cultured ex vivo. The apparent absence of viral
gene expression by unstimulated cells cultured ex vivo is
discordant with the relatively high level of gene expression
observed in vivo. The explanation for this intriguing observation
remains elusive and will require further study. It is possible that
tissue-resident progeny not sampled in this study maintain a
different level of HIV gene expression than circulating CD4+
T cells.
In summary, our work provides evidence that HSPCs are a
functionally significant reservoir of persistent HIV infection.
Proviral genomes from HSPCs are associated with expanded
clonal HIV proviral genomes found in peripheral blood and
bone marrow that contribute to residual PV. These studies
shed light on how the latent reservoir is maintained in vivo
and suggest a need for novel therapeutic options. Selective
targeting of HIV-infected progenitor cells may reduce the
number of clonally expanded HIV proviral genomes, promote
a reduction of the HIV reservoir, and limit residual and
rebound PV.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
CD133 monoclonal antibody, phycoerythrin conjugated Miltenyi Biotec Cat# 130-090-853, clone 293C3;
RRID:AB_244346
CD133 monoclonal antibody, biotin conjugated eBioscience Cat# 13-1338-80, clone AC133;
RRID:AB_1210585
CD34 monoclonal antibody, fluorescein isothiocyanate
conjugated
BD Biosciencess Cat# 555821, clone 581;
RRID:AB_396150
CD3 monoclonal antibody, allophycocyanine conjugated eBioscience Cat# 17-0037, clone OKT3;
RRID:AB_1907373
CD3 monoclonal antibody, phycoerythrin conjugated eBioscience Cat# 12-0037-42, clone OKT3;
RRID:AB_1272078
CD3 monoclonal antibody, Pacific Blue conjugated BioLegend Cat# 317314, clone OKT3;
RRID:AB_571909
HIV gag, PE (RD-1) conjugate Beckman Coulter Cat# 6604667, clone KC57
HIV gag ELISA capture antibody NIH AIDS Reagent Program Cat# 3537, clone 183-H12-5C
HIV gag ELISA detection antibody, purified from
hybridoma ascites
ATCC Cat# HB-9725, clone 31-90-25
Bacterial and Virus Strains
E. coli Stbl2 Fisher Cat# 10268019
Biological Samples
Fetal bovine serum, qualified, non-US origin,
USDA-approved regions
GIBCO Cat#10437028
Human AB serum Fisher Cat# BP2525-100
Total Control RNA (from Raji cell line) Invitrogen Cat# 4307281
Chemicals, Peptides, and Recombinant Proteins
Ficoll-Paque PLUS media GE Healthcare Cat# 17-1440-02
StemSpan SFEM StemCell Technologies Cat# 09650
Hybri-Max dimethyl sulfoxide Millipore Sigma Cat# D2650-100ML
Tumor necrosis factor alpha (TNFa) R&D Systems Cat# 210-TA-005
Streptavidin, Pacific Blue conjugated Invitrogen Cat# S-11222
Trizol Reagent Invitrogen Cat# 15596026
DNase I, Amp grade Invitrogen Cat# 18068015
Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich Cat# P1585-1MG
Ionomycin calcium Sigma-Aldrich Cat# I0634-1MG
Trizol LS Reagent Invitrogen Cat# 10296028
qScript Flex cDNA Synthesis kit Quanta Biosciences Cat# 101414-112
qScript cDNA Supermix Quanta Biosciences Cat# 101414-108
Phusion Hot Start II High Fidelity DNA polymerase Fisher Cat# F549L
GelRed nucleic acid gel stain, 10,000X in water Biotium Cat# 41003
TaqMan Gene Expression MasterMix Applied Biosystems Cat# 4369016
TaqMan Fast Advanced MasterMix Applied Biosystems Cat# 4444557
Polyethylenimine Polysciences Incorporated Cat# 23966-2
Plasmocin InvivoGen Cat# ant-mpt
Nunc Immuno Maxi-Sorp 96 well plate Fisher Cat# 12-565-135
Streptavidin Poly-HRP40 Fitzgerald Industries International Cat# 65R-S104PHRP
HIV-1 p24 core antigen, ELISA standard ViroGen Cat# 00177-V
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Critical Commercial Assays
CD133 MicroBead Kit - Hematopoietic Tissue, Human Miltenyi Biotec Cat#130-100-830
StemSep CD34 Positive Selection Cocktail StemCell Technologies Cat#14756
CD4 MicroBead sort kit, untouched Miltenyi Biotec Cat# 130-096-533
CD4 MicroBeads Miltenyi Biotec Cat# 130-045-101
ACTB TaqMan Gene Expression assay, FAM-MGB Applied Biosystems assay ID Hs99999903_m1
POLR2A TaqMan Gene Expression assay, FAM-MGB Applied Biosystems Assay ID Hs00172187_m1
pcDNA3.1/V5-His-TOPO kit Invitrogen Cat# K480001SC
Pierce EZ-Link Micro Sulfo-NHS-Biotinylation Kit Fisher Cat# PI-21925
Deposited Data
Sequence files GenBank MH895379 -MH897920
Experimental Models: Cell Lines
ACH-2 NIH AIDS Reagent Program Cat# 349; RRID:CVCL_0138
293T ATCC Cat# CRL-3216; RRID:CVCL_0063
CEM-SS NIH AIDS Reagent Program Cat# 776
MOLT4-R5 NIH AIDS Reagent Program Cat# 4984
Oligonucleotides
See Table S7 for PCR primers N/A
Recombinant DNA
pVQA NIH AIDS Reagent Program Cat# 12666
pNL4-3-DGPE-GFP McNamara et al., 2012 N/A
p436-5LTRdel This paper N/A
pCMV-HIV-1 S.-J.-K. Yee (City of Hope
National Medical Center)
N/A
pVSV-G Nancy Hopkins (Massachusetts
Institute of Technology)
N/A
p409HX-gagGFP This paper N/A
p421HX-gagGFP This paper N/A
p439BX-gagGFP This paper N/A
p454BX-gagGFP This paper N/A
pHIV454304 This paper N/A
p89.6 R.G. Collman (University of
Pennsylvania)
NIH AIDS Reagent Program Cat# 3552
Software and Algorithms
FlowJo https://www.flowjo.com; RRID:SCR_008520
Lasergene suite (SeqMan, SeqBuilder) DNAStar V10.1.1; RRID:SCR_000291
MEGA7 (Kumar et al., 2016) https://www.megasoftware.net
Poisson distribution calculator https://keisan.casio.com/exec/system/
1180573179
HIVAlign Los Alamos National Laboratory https://www.hiv.lanl.gov/content/
sequence/VIRALIGN/viralign.html




100 mm nylon cell strainer, sterile Falcon Cat# 352360
MACS MS columns Miltenyi Biotec Cat# 130-042-201
MACS LS columns Miltenyi Biotec Cat# 130-042-401
MiniMACS Separator Miltenyi Biotec Cat# 130-042-102
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Kathleen
Collins (klcollin@med.umich.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human subjects
Fifty-three HIV-infected individuals were recruited through the University of Michigan HIV-AIDS Treatment Program and the Henry
Ford Health System. Written informed consent was obtained according to a protocol approved by the University of Michigan
Institutional Review Board and Henry Ford Institutional Review Board (U-M IRB number HUM00004959 and HFH IRB number 7403).
Donors were between 21 and 69 years old (Table S1), with normal white blood cell counts and plasma viral loads < 48 copies/mL for at
least 6 months on antiretroviral therapy (Table S1). We obtained 100 mL of peripheral blood and 20 mL of bone marrow from most
donors. The 43 donors who met the sample inclusion criteria were comprised of 38 males and 5 females (Table S1). We did not note
sex differences in our ability to detect provirus in donor HSPCs or in the detection of residual PV that matched HSPC provirus. How-
ever, this study was not designed to detect such differences. The smaller number of females thanmales recruited to the study greatly
limits this analysis. 41 subjects initiated therapy in chronic phase of HIV-1 infection, twomales began therapy in the acute/early stage.
All collected samples were coded and anonymized. A sample size of approximately 50 subjects was chosen based on a power calcu-
lation that assumed half the HSPC samples would be positive. We estimated that with a sample size of 50 subjects we could be 95%
certain that our estimate of the prevalence of HSPC harboring infectious provirus would be accurate to within 7%.
Cell lines
293T cells were authenticated by genotyping performed by the Duke DNA Analysis Facility and grown in DMEM. CEM-SS cells were
genotyped but not authenticated as a genotyped comparison cell line was not available to Duke DNA Analysis Facility. CEM-SS,
MOLT4-R5 and ACH2 cells were grown in RPMI-1640 plus 10mM HEPES. All cells were grown in medium supplemented with
100 Units/mL penicillin, 100 mg/mL streptomycin, 2 mM glutamine, 10mM HEPES and 10% fetal bovine serum. All cell lines were
maintained at 37C in 5% CO2 humidified atmosphere.
METHOD DETAILS
Donor cell isolation and fractionation
Isolation of bone marrow mononuclear cells (BMMC)
Bone marrow was aspirated from the posterior iliac crest into 10 cc syringes containing 0.5 mL heparin. Cell and plasma isolations
were performed in a dedicated clean room distinct from PCR set up and product gel analysis areas to minimize potential contami-
nation. Marrow was expelled into a 50mL conical tube and diluted with one volume bonemarrow wash buffer (BMWash), which was
composed of phosphate buffered saline [PBS (Invitrogen)], 10% FBS and 2 mM EDTA (Lonza). The diluted marrow was passed
through a 100 mm nylon cell strainer by gravity flow. The marrow was further diluted and overlayed on Ficoll-Paque for gradient
separation at 720 x g for 30 min at 25C, acceleration setting 2, deceleration setting 2. After the separation, bone marrow plasma
in the upper layer was carefully removed and filtered through a 0.2 mm pore to remove cells and stored at 80C. Bone marrow
mononuclear cells (BMMC) at the plasma/Ficoll interface were pooled, washed with BM Wash, and incubated in 20 mL StemSpan
SFEM in a prone T75 culture flask for 1.5 – 2 hours at 37C in 5% CO2. Non-adherent cells were removed by gently rolling the flask
and pipetting. Flasks were rinsed with 5 mL cold MACS Buffer (2% FBS, 2 mM EDTA in PBS) and detached cells were pooled with
non-adherent cells.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
MidiMACS Separator Miltenyi Biotec Cat# 130-042-302
MACS MultiStand Miltenyi Biotec Cat# 130-042-303
Pre-Separation filter, 30 mm Miltenyi Biotec Cat# 130-041-407
MagNA Pure Compact Roche Cat# 03731146001
MagNA Pure LC Total Nucleic Acid Isolation kit Roche Cat# 03246779001
Low retention, RNase-, DNase-free 1.5 ml tubes Denville Scientific Cat# C2171
NucleoSpin Gel and PCR Clean Up Columns Macherey-Nagel Cat# 740609.250S
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Purification of CD133+ cells (sort 1)
CD133+ BMMCs were purified using the CD133 MicroBead Kit – (Hematopoietic Tissue, Human) according to the manufacturer’s
protocol for maximal purity with the following modifications: for donations 453000 and onward, we used 1.5 times the recommended
bead to cell ratio to increase CD133+ cell recovery. MACSMS columns in a MiniMACSmagnetic separator or MACS LS columns in a
MidiMACSSeparator on aMACSMultiStand (Miltenyi Biotec) were prepared, depending on the number of cells to be sorted. A 30 mm
pore Pre-Separation filter was placed over the first of the two columns used in maximal purity protocol, and columns and filter were
equilibrated with MACS Buffer before applying cell samples. Each column was washed twice. Sort purity was ascertained at each
step by analyzing an aliquot for CD133, CD34, and CD3 expression by flow cytometry (see below).
Isolation of CD34+ cells (sort 2)
The flow through cells from the first columnwere used for the second sort in which CD133-depleted CD34+ HSPCswere isolated. For
CD34+ cell isolation, flow through cells were concentrated to 200 million cells/mL in MACS Buffer then the StemSep CD34 Positive
Selection kit was applied and incubated according to the manufacturer’s instructions for maximal purity. MACS Buffer and columns
were substituted for washes and magnetic separation as described for the CD133 sort (sort 1). Sort purity was ascertained at each
step by analyzing an aliquot for CD133, CD34, and CD3 expression by flow cytometry (see below).
Following purification, HSPCs and matching numbers of flow through cells were washed with 4 mL of StemSpan medium and
divided into equal aliquots for DNA extraction on a MagNAPure Compact Nucleic Acid Isolation unit and cryogenic preservation
in 10% Hybri-Max DMSO in FBS. The bulk flow through of the second sort was viably frozen and served as a source of non-
HSPC BMMCs.
Isolation of BMMC CD4+ cells for viral outgrowth assay
Bulk flow through cells described above were quick-thawed at 37C and washed twice with R10 medium supplemented with
40 U/mL DNase I (Sigma). CD4+ cells were isolated by negative selection with the CD4 MicroBead Sort Kit, Untouched, according
to the manufacturer’s protocol.
Plasma virus and peripheral blood mononuclear cell (PBMC) isolation
100 mL of peripheral blood was collected into 10 mL purple top ethylenediaminetetraacetic acid dipotassium salt vacutainer
tubes (BD) on the same day as the bone marrow aspirate. The blood was diluted with PBS, then overlayed onto Ficoll-Paque.
Gradient separation was performed as described for bone marrow samples. Following the centrifugation, plasma was filtered
through a 0.2 mm pore to remove cells. Virus was pelleted at 112,400xg for 1.5 – 2 h at 4C. Viral pellets were resuspended with
1 mL TRIzol Reagent and stored at 80C until RNA extraction. Mononuclear cells at the plasma:Ficoll interface were washed twice
with PBS before extracting DNA from two aliquots of 106 cells and viably freezing the remainder.
CD4+ cells were positively selected from thawed PBMC by incubation with CD4MicroBeads at a 50% higher bead:cell ratio than in
the product insert and sequential isolation over two MACS MS columns. Bead bound CD4+ cells were depleted of adherent cells
overnight at 37C in R10 medium in a tissue culture treated 6 well plate. DNA was extracted from one million cells with a MagNAPure
Compact Nucleic Acid Isolation unit.
Flow cytometry and antibodies
All cell samples were fixedwith 2%paraformaldehyde (Sigma) in FACSBuffer (2%FBS, 1%human AB serum, 2mMHEPES, 0.025%
sodium azide (Sigma) in PBS without calcium or magnesium) for 30 minutes at room temperature before acquisition on a BD
Biosciences FACSCanto cytometer or FACScan cytometer with Cytek 6-color upgrade.
Flow cytometric analysis of cell purity
BMMC aliquots removed for purity assessment were stored at 4-8C overnight before staining. The purity of the recovered HSPC
populations was measured for expression of the following human proteins: CD133 [phycoerythrin (PE) conjugated or biotin-
conjugated with streptavidin-Pacific blue], CD34 [conjugated with fluorescein isothiocyanate (FITC)], CD3 [conjugated with
allophycocyanine (APC), PE, or Pacific Blue]. Nonviable cells were identified and excluded from analyses by staining with
1 mg/mL 7-aminoactinomycin D (7-AAD, Sigma) or 40 ng/mL 4,6-Diamidino-2-phenylindole (DAPI, Pierce) in FACS Buffer. An un-
stained pre-adherence depletion cell sample, isotype controls and single-color compensation controls using OneComp eBeads
(eBioscience) were processed in parallel to aid acquisition and compensation settings.
Flow cytometric analysis of GFP expression by transfected and transduced cells
Transfected 293T cells were washed once in PBS, detached from the plate with 0.05% trypsin EDTA (GIBCO), and fixed with 2%
paraformaldehyde for 30 minutes at room temperature. Transduced suspension cells were fixed as described for 293T cells.
Expression of GFP was assessed on viable cells gated by light scatter.
Flow cytometric analysis of intracellular Gag stain to measure infection
Cells treated with virus were fixed in 2% paraformaldehyde for 30 minutes at room temperature, permeabilized in 0.1% Triton
X-100 (Fisher) at room temperature for 5 minutes, and stained with PE-conjugated anti-Gag antibody at room temperature for
20 min. Fluorescence was measured on a BD FACScan cytometer with Cytek 6-color upgrade. Cells were gated by forward
scatter versus side scatter, and infected cells were gated by Gag-PE versus side scatter using mock infected cells to set the
Gag+ gate.
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DNA extraction
Cellular DNA was prepared using a MagNA Pure Compact System in room one of the two dedicated PCR clean rooms described
below. Cell suspensions in PBS were extracted with program ‘‘DNA Blood 100_400’’ and with the ‘‘Cultured cells’’ setting.
RNA isolation
RNA was prepared in room one of the two dedicated PCR clean rooms described below. In addition, work space, pipets and equip-
ment surfaces were wiped down with RNase Away (Invitrogen) to reduce RNase transfer before handling samples and reagents.
Plasma virus RNA isolation
Frozen samples in TRIzol were thawed at room temperature. Two micrograms of control human Raji cell line RNA were spiked into
donor TRIzol samples prior to organic extraction to serve as carrier for improved RNA recovery as well as a means to monitor
RNA extraction and reverse transcription efficiency. A separate tube of TRIzol and Raji RNA was prepared as a reagent only control.
A fresh aliquot of chloroform was prepared daily and the organic extraction was performed according to the manufacturer’s direc-
tions. The aqueous phase of the TRIzol suspensions was further purified with the RNeasy Micro kit (QIAGEN). Samples were divided
into two aliquots and processed according to the manufacturer’s protocol except that the DNase step was performed after RNA
elution as described below as we found this achieved a higher yield. RNA was eluted with 20 mL of RNase-free water.
DNase treatment was performed immediately before reverse transcription. Enzyme reactions were prepared on ice or in a cooler
rack. RNA samples were divided into two 20 mL reactions containing 2U of Amp Grade DNaseI and 10 mL RNA following the man-
ufacturer’s protocol.
Viral outgrowth supernatants
For RNA isolation from viral supernatants, we harvested supernatants from 5 million CD4+ cells cultured in 1mL of R10 medium
supplemented with: 0.3% DMSO solvent control or 50 ng/mL PMA and 1 mM ionomycin incubated at 37C in 5% CO2 for 48 hours.
Culture supernatants were centrifuged at 700xg for 5 minutes to remove cells and debris, and were processed as previously pub-
lished (Laird et al., 2015) using TRIzol LS reagent according to the manufacturer’s protocol with the modification that 1 mg of Raji
RNA was added to the TRIzol LS to allow for quantification of the efficiency of RNA recovery. RNA was dissolved in 10 mL
RNase-free water.
Cellular RNA extraction
Cellular RNA was extracted using the QIAGEN RNeasy kit according to the manufacturer’s protocol. Samples were frozen at 80C
after homogenization with QIAGEN Qiashredders and thawed at room temperature to complete sample binding, on-column DNase
digestion with QIAGEN RNase-free DNase set, and elution in 22 mL water.
Reverse transcription
Reactions were performed for each sample as described below. RNA samples were treated with DNase prior to reverse transcription
and/or a reverse transcriptase leave-out was performed to avoid and/or detect contaminating HIV DNA contributing to the down-
stream qPCR signal. In all samples tested, reverse transcriptase leave-out controls were negative. Control samples indicated that
DNase treatment was fully effective.
Plasma virus RNA
Plasma virus cDNA synthesis with oligo dT priming was performed using the qScript Flex cDNAKit scaled up from themanufacturer’s
protocol to 200 mL final reaction volumes incubated in 50 mL aliquots. cDNA was pooled and transferred to a low retention 1.5 mL
snap cap tube and stored at 20C.
CD4+ T cell supernatants (VOA)
RNAwas reverse transcribed with qScript cDNA SuperMix per manufacturer’s instructions scaled up to 200 mL reactions. cDNA was
pooled and concentrated to 30 mL in Buffer EB with the QIAQuick PCR Purification kit (QIAGEN) according to the kit protocol.
Cell-associated RNA
cDNA was generated from cell-associated RNA as described for the viral outgrowth assay, but in 50 mL reactions per sample which
were tested without volume reduction.
PCR contamination control procedures
To minimize carryover and cross contamination with lab strains, three separate work rooms were used for cell and nucleic acid isola-
tion, PCR reaction set up, and amplified product analysis. Work flow proceeded unidirectionally each day. The first room was for
tissue preparation and nucleic acid extraction, as described above. The PCR set-up room (room 2) utilized a dedicated still air
hood for reagents and unamplified templates and a separate hood for adding first round PCR products to reactions. Hoods were
wiped down with 10% bleach and 70% ethanol before commencing any work. The entire interior of each hood was decontaminated
with 10%bleach andUV irradiationmonthly. Reactionswere assembled and stock tubes removed before tubes containing DNAwere
opened. Gloves were changed after handling template and before touching refrigerator or freezer handles. First round PCR products
were added to second round reactions while wearing disposable sleeve protectors. Second round products were never opened in
the reaction set-up room. Tubes containing stock solutions were not opened after handling amplified DNA. Gel loading and DNA
extraction from gel bands occurred in the third room.
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SGA
Cellular genomic DNA or cDNA prepared from plasma were used in a two-step, limiting dilution SGA reaction. The cut off for limiting
dilution was 30% positive reactions in the donor samples. ACH2 cells, which stably harbor one copy of the HIV genome were used
for this as a positive control. PBMCDNA from each donor was used to select optimal primers for detection of HIV from that donor. All
PCRs were 50 mL reactions containing 1X Phusion Buffer HF, 200 nM dNTP (from 100 mM dNTP set, Roche), 500 nM each primer,
and 1 U Hot Start II High Fidelity DNA Polymerase. First round reactions received 5 mL DNA or cDNA template, second round
reactions amplified 1-2 mL of the first-round reaction. Primer sequences and sources are listed in Table S7.
Gag/env multiplex SGA PCR
First round reactions were multiplexed for LTR/gag with 50 LTR forward primer U5-557.9662-f and either tagD4.6b-p24R1d or
long1316-D4.6b Dengue-tagged gag reverse primer, and env C2-V3 with forward primer C2F2 and reverse primer C4R1. Reactions
were denatured at 98C for 30 s, followed by 35 cycles of 98C for 10 s, 68C for 10 s, and 72C for 25 s, with a final extension at 72C
for 5minutes. For some donors, alternative primers were used because of sequence variation. If first round primers extending from vif
(5036d) or tat (5956d) to the 30 LTR (LTR-pA-R) were used instead, the 72C extension time per cycle was 2 minutes and the final
extension was for 10 minutes. For full length envelope amplification, first round primers were 5036d and LTR-pA-R.
Second round LTR-gag PCRwere performedwith primers 626 s and Dengue tag D4.6b and incubated at 98C for 30 s, followed by
35 cycles of 98C for 10 s, 70C for 10 s, and 72C for 40 s and a final extension at 72C for 10 minutes. Second round env C2-V3
reactions consisting of forward primer env1in5 and reverse primer env1in3 were incubated at 98C for 30 s and were cycled 40 times
at 98C for 10 s, 56C for 10 s, and 72C for 15 s, concluding with a 5 minute extension at 72C. Cycling conditions for second round
reactions spanning full length env (primers 5956d and LTR-pA-R) began with denaturation at 98C for 30 s, followed by 35 cycles of
98C for 10 s, 71C for 10 s, and 72C for 2 minutes, with a final incubation at 72C for 10 minutes. Some donor viruses required an
alternative hemi-nested LTR-gag primer set U5-577.9662-f and 1294r, and were incubated at 98C for 30 s with 35 cycles of 98C for
10 s, 64C for 10 s, and 72C for 40 s, and a final extension at 72C for 5 minutes.
Optimal amplification of env C2-V3 from donors 409000, 415000, 421000 and 432000 required donor specific primers which were
designed for compatibility with the cycling conditions described for primer sets C2F2/C4R1 and env1in5/env1n3.
Near full length genome PCR
For detection of intact near full length proviral genomes, first round reactions performed at limiting dilution (fewer than 30% positive
reactions) for the amplification of single genomes. Reactions contained primers U5-577.9662-f and a Dengue-tagged version of
LTR-pA-R (Sebastian et al., 2017). The incubation conditions were 98C for 30 s, 35 cycles of 98C for 10 s, 67C for 10 s, and
72C for 4 minutes, followed by 72C for 10 minutes. First round reactions were screened for the presence of env C2-V3. Only
reactions with open reading frames were further amplified to generate a hemi-nested second round product of approximately
9 kilobase pairs (kbp) and/or three overlapping sub-genomic regions. The hemi-nested reaction contained forward primer 626 s
and either LTR-pA-R or tag primer D4.6b and was incubated at 98C for 30 s and cycled 35 times at 98C for 10 s, 70C for 10 s,
and 72C for 4 minutes followed by incubation at 72C for 10 minutes.
In some cases, we also amplified overlapping subgenomic fragments consisting of a 700 bp gag product (from U5-577.9662-f
and 1294r primers), a 3.7 kbp fragment (from 5956d in vif and LTR-pA-R through the poly adenylation site), and a 5.3 kbp fragment
(from the 30 end of gag to 50 end of env amplified with primers 1204s and E30HX rc). The three overlapping fragments have exactly
matching overlaps ranging from 67-461 base pairs.
The cycling conditions for the 3.7 kbp and 700 bp fragments are described above. The cycling conditions for the 5.3 kbp fragment
were 98C for 30 s, followed by 35 cycles of 98C for 10 s, 66C for 10 s, and 72C for 2 minutes 40 s, and ended with 10 minutes at
72C. All reactions were amplified in a BioRad C1000 thermocycler.
PCR amplification of integration sites
Amplification of integration sites used amodification of an assay that was previously published (Liu et al., 2006). The assaywasmodi-
fied by the design of new primers that allowed the inclusion of the 50 deleted region described in Figure 1 along with the integration
site. To improve restriction digestion and ligation efficiency, MagNA Pure DNA elution buffer was removed by ethanol precipitation
and the DNA was resuspended to the original volume with QIAGEN Buffer EB (10 mM Tris). Recovered DNA was digested in 50 mL
with PstI at 37C x 5 hours followed by an incubation at 80C x 30 minutes, then applied to a 200 mL ligation reaction containing
1X Ligation Buffer with 1 mM ATP and 3200 units T4 DNA Ligase (New England Biolabs). Ligation reactions were divided into
50 mL aliquots and incubated at 16C for 15 hours followed by 80C for 30 minutes. 5 mL of ligation reaction was added to 50 mL
PCR for a total of 80 reactions. First round cycling was performed using primers outer LTR3 and outer gag at 98C for 30 s for an
initial cycle followed by 35 cycles of 98C for 10 s, 63C for 10 s, and 72C for 2 minutes. A final incubation was performed at
72C for 5 minutes. Second round PCR was performed with primers inner LTR3 and inner gag at 98C for 30 s for the initial cycle
followed by 30 cycles of 98C for 10 s, 66C for 10 s, and 72C for 2 minutes. A final incubation was performed at 72C for 5 minutes.
Potential integration sites were purified from gel bands and sequenced.
Once the integration site was identified and sequenced, we designed primers outer Chr9 and inner Chr9 to amplify additional
copies. These primers were used with HIV inner LTR3 reverse primer to generate amplicons. Five mL of genomic DNA were added
neat to 80 - 50 mL first round PCR reactions and incubated at 98C for 30 s on the initial cycle followed by 35 cycles of 98C for 10 s,
70C for 10 s, and 72C for 40 s.We also included a final incubation of 72C for 10minutes. One mL of first round product was added to
second round reactions, which were cycled under the same conditions as the first round.
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Gel extraction of DNA fragments
Amplicons were purified from TAE (40 mM Tris, 20 mM acetate, 1 mM disodium EDTA; Fisher)/agarose (Fisher) gels containing
1X GelRed with the QIAQuick Gel Extraction kit (QIAGEN) according to the manufacturer’s instructions with the following modifica-
tions: Nucleospin Gel and PCR Clean-up Columns were substituted for kit columns and maximum sample and wash volumes were
reduced to 650 mL. Buffer PE wash and Buffer EB elutions were incubated for 4 minutes at room temperature before centrifugation
through the column membrane. Eluates were sequenced directly in both directions by the Sanger method at the University of
Michigan DNA Sequencing Core.
Quantitative reverse transcription PCR (qRT-PCR)
All qRT-PCR reactions were cycled on an Applied Biosystems 7300 thermocycler, with the following conditions: 50C for 2 minutes,
then 95C for 10 minutes, followed by 45 cycles of 95C for 15 s and 60C for 60 s.
Viral supernatants
Plasma and supernatant cDNA yields were determined by quantitative real-time RT-PCR for b-actin mRNA (ACTB). cDNAs were
diluted 1:10 and assayed with TaqMan Gene Expression MasterMix or Taqman Fast Advanced Gene Expression MasterMix as
previously described (Laird et al., 2015). A cDNA synthesis reaction performed on 500 ng of direct input Raji RNA was serially diluted
to generate a standard curve.
HIV mRNA was quantified with primers forward 9501 mRNA-F, reverse 9629-polyA-R and 0.25 mM probe L9531FM as previously
described (Bullen et al., 2014) with either Taqman FAST Gene Expression MasterMix or Taqman Gene Expression MasterMix. HIV
mRNA was assayed on the same plate as the no reverse transcriptase and b-actin reactions. Standard curves were generated by
serial dilution of the pVQA HIV plasmid down to 10 HIV copies.
Cellular RNA
Levels of HIVmRNA in VOA and 436 50LTR deletion cell-associated RNAwere quantified as for supernatants. RNA input was normal-
ized for POLR2A levels. A standard curve was prepared by serially diluting one sample from neat to 10,000-fold diluted, while all
experimental samples were diluted 10-fold for comparison to the standard curve.
Construction of reporter constructs and infectious proviral genomes
Generation of reporter construct containing the deletion identified in donor 436000 (p436-5LTRdel)
A 2238 bp DNA fragment containing the donor 436000 50LTR and gag sequence within NL4-3-DGPE-GFP BstZ171 to SwaI sites
(see Figure S6) was synthesized by GenScript with flanking 50 SalI and 30 XbaI restriction sites and cloned by GenScript into the
multiple cloning cassette of pUC18, the same vector as the parental viral plasmid for NL4-3-DGPE-GFP. The synthesized DNA
was verified by sequencing. The 2.7 kbp AatII to SwaI fragment was gel purified using the QIAquick Gel Extraction kit according
to the manufacturer’s protocol, but substituting NucleoSpin Gel and PCR Clean-up Columns. This fragment was ligated into
NL4-3-DGPE-GFP plasmid DNA digested with the same enzymes. Diagnostic digests confirmed the isolation of the desired plasmid
(p436-5LTRdel).
Synthesis of LTR reporter constructs from donor LTR sequences
To test the activity of LTR sequences from intact near full length HSPC provirus recovered from donors 409000, 421000, 439000 and
454304, LTR-driven Gag-EGFP (GenBank: LC311024.1) fusion inserts were synthesized by Thermo to provide reporter constructs
and cloning intermediates for 454304 reconstruction. Because of problems with PCR amplifying duplicated sequences, HIV near
full-length PCR does not completely regenerate full LTRs at each end. For synthetic reconstruction, full LTR sequences were inferred
from the available donor derived sequences for all but 89 (40900, 421000, 454304) or 108 bp (439000). This small gapwas filled in with
NL4-3 sequence. In some cases, additional gag sequence was also included to allow for the possibility of full genomic reconstruction
in the future. This resulted in some variation in the resultant Gag-GFP fusion protein. The synthetic constructs were provided in
Thermo’s pMK (p421HX-gagGFP, p439BX-gagGFP, p454BX-gagGFP) or pMS (p409HX-gagGFP) plasmids along with quality
control sequence verification. LTR-gag regions were independently confirmed by sequencing.
Reconstruction of donor proviral genomes to produce infectious virus
The donor 454304 near full length genome amplicon generated by PCR with primers U5-577.9662-f and LTR-pA-R was gel purified
and TOPO cloned with the pcDNA3.1/V5-His-TOPO kit. To accomplish this, the PCR product was desalted with the QIAQuick PCR
Purification kit according to QIAGEN’s protocol. An A-overhang was added with Taq DNA polymerase (New England Biolabs) and
1 mM ATP (Roche) at 70C for 20 minutes before combining with salt solution and vector provided in the TOPO kit in proportions
recommended for chemical transformation. The TOPO product was transformed into competent Stbl2 cells according to the
manufacturer’s instructions and DNA minipreps were screened with SbfI and KpnI (New England Biolabs). Potentially intact clones
were regrown for larger scale plasmid isolation to completely sequence the HIV insert.
Thewhole genome for the near full-length genome isolated fromdonor 454304DNAwas reconstructed by inserting the BsshII-XhoI
fragment from the TOPO-cloned PCR product into the corresponding LTR vector using a three-way ligation strategy using fragments
generated with XhoI, FspI and BssHII digestions. Transformed Stbl2 cultures were grown at 30C to minimize deletions. Colonies
were screened for the correctly ligated product by digesting individually with HindIII-HF, XhoI, FspI, and BssHII (all fromNew England
Biolabs). The properly reconstructed plasmid, pHIV454304, lacked the GFP reporter and contained the complete, fully infectious HIV
genome.
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Transfections and virus production
HEK293T cells were seeded to provide 50%–75% confluence at the time of transfection. 24 hours post-seeding, cells were trans-
fected using a 1:4 mass ratio of DNA:polyethylenimine in 150 mM NaCl. Where pCMV-HIV-1 and pVSV-G plasmids were included,
they were added in equal mass ratios with DNL4-3-DGPE-GFP or LTR construct plasmids. DNA and polyethylenimine were gently
vortexed for 10 s and incubated at room temperature for 15minutes. The transfection solution was then added to the plate drop-wise
while agitating, and the cells were maintained at 37C, 5% CO2. 48 hours post-transfection, viral supernatants were collected and
clarified by pelleting cell debris at 500-1,000xg for 5-15 minutes, aliquoted and stored at 80. To achieve higher viral titers, equal
copy numbers of HIV RNA from the wild-type NL4-3-DGPE-GFP or LTR-deleted viral supernatants were concentrated by ultracen-
trifugation at an average RCF of 50,000xg for 2 hours. Viral pellets were resuspended in D10 medium with 56 mg/mL plasmocin and
used for transductions.
HIV p24 ELISA
Gag p24 capture antibody was diluted to 1 mg/ml in carbonate coating buffer (100 mMNaHCO3, 32.35 mMNa2CO3 in water). 100 mL
of the antibody mixture was applied per well of Nunc Immuno Maxi-Sorp 96 well plates and incubated at 4C for at least 16 hours.
Antibody coated plates were used within 2 weeks of coating. Before use, each well was washed 3 times with wash buffer [200 mM
NaCl, 0.05% Tween-20 (both from Fisher) in PBS] and blocked with blocking buffer [1% casein (Sigma) in PBS] for 45 min.
Supernatant from HIV transfected or infected cultures was clarified at 6000xg for 5 minutes and serially diluted in ELISA lysis buffer
(0.05% Tween-20, 0.5% Triton X-100, 0.5% casein in PBS) to produce readings within the dynamic range of the standard curve. HIV
p24 core antigen was also diluted in lysis buffer to generate a standard curve from 1.5625 to 100 ng/mL. Plain lysis buffer was used to
blank absorbance readings. 100 mL were applied per well and incubated for 2 hours at room temperature. The plates were then
washed four times with a 1 minute incubation per wash. Anti-p24 detection antibody was biotinylated using EZ-Link Micro Sulfo-
NHS-Biotinylation kit per manufacturers protocol. 0.5 mg/mL biotinylated antibody in diluent buffer (0.5% casein, 0.5% Tween-20
in PBS) was applied to eachwell, incubated at room temperature for 1 hour thenwashed before addition of 1 mg/mL strepavidin-horse
radish peroxidase (Streptavidin Poly-HRP40). The plates were incubated for 30minutes, washed, and developed with TMB substrate
(3, 30, 5, 50 tetramethylbenzidine, Sigma) for 20 minutes. The reaction was stopped by adding 1/4 volume of 0.5M sulfuric acid (Mal-
linckrodt) and mixing gently. Absorbance was read at 450 and 650 nm. Peroxidase activity was calculated as A450 minus A650 and
p24 concentration interpolated from the standard curve.
HIV transduction and infection of T cell lines
Transduction of CEM-SS cells and infection of MOLT4-R5 cells were by spin inoculation at 1050-1400xg for 2 hours at 25C in
medium containing 4 mg/mL polybrene (Sigma). Transduction was monitored by GFP expression while infection was quantified by
intracellular Gag expression as described in the flow cytometry section.
QUANTIFICATION AND STATISTICAL ANALYSIS
Donor and sample exclusion criteria
Ten donors were excluded due to lack of sufficient volume of bone marrow, HSPC sort purity below 80%CD133+ (sort 1) and CD34+
(sort 2), > 1% CD3+ cells, or inability to assess CD3+ T cell content in HSPC population at any donation time point. For the included
donors, there were instances where one sort had adequate purity, but the other did not. These exclusions are summarized in
Figure S1A. Proviral sequences from HSPC samples were subjected to a statistical test for likelihood that they were contributed
by contaminating T cells (see legend for Figure S1). Hypermutated sequences were not excluded from phylogenetic trees but
were excluded from the average pairwise distance calculation presented in Table S4 as is standard.
Phylogenetic Analysis
Condensed consensus Maximum Likelihood phylogenetic trees of all gag and env C2-V3 amplicons were estimated for appropriate
clustering. Individual donor phylogenetic trees were inferred by using the Maximum Likelihood method based on the Hasegawa-
Kishino-Yano model (Hasegawa et al., 1985). Initial tree(s) for the heuristic search were obtained automatically by applying
Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated using the Maximum Composite Likelihood (MCL)
approach, and then selecting the topology with superior log likelihood value. A discrete Gamma distribution was used to model
evolutionary rate differences among sites [5 categories (+G, parameter values as noted)]. Codon positions included were
1st+2nd+3rd+Noncoding. All positions with less than 95% site coverage were eliminated. HIV sequence database tools on the
Los AlamosNational Laboratory website were used to translate HIV genes (HIVAlign) and determine if sequences were hypermutated
(HyperMut).
Statistical analyses
Statistical details of experiments can be found in Figure legends. All results are expressed as the mean ± SD unless otherwise
specified. Comparison of proportions of sequence populations was performed using online calculators for two-tailed Z-test compar-
ison of 1 or 2 sample proportions (https://www.socscistatistics.com/tests/ztest). P values were determined using two-tailed
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Wilcoxon matched pairs signed rank test except for Table S3, which utilized two-tailed student’s t-test. All experiments were
repeated in at least two independent experiments unless otherwise indicated in the figure legend.
DATA AND SOFTWARE AVAILABILITY
The accession numbers for the HIV sequences from donor cells and tissues reported in this paper are Genbank: MH895359- Genbank:
MH897920.
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